Recruiting
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis - IM101-240
Updated:
1 May, 2023
|
ClinicalTrials.gov
Gender(s)
Age Range
Location(s)
Recruiting
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Diagnosis of JIA (any subtype) - Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept - Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial - Parent or legally acceptable representative willing to participate in the study and sign the informed consent Exclusion Criteria: - Pregnant or nursing female at the time of enrollment - Prior malignancies if the patient has not been malignancy free for at least 5 years. - Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study - Known poor compliance with clinic visits (based on physician judgment)
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001